Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 342

1.

The ESC Risk Score is Less Reliable than ACC/AHA Risk Factors in Hypertrophic Cardiomyopathy: When Sensitivity Trumps Specificity.

Maron MS, Rowin EJ, Maron BJ.

Can J Cardiol. 2019 Jun 24. pii: S0828-282X(19)30434-9. doi: 10.1016/j.cjca.2019.06.018. [Epub ahead of print] No abstract available.

PMID:
31703825
2.

Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry.

Neubauer S, Kolm P, Ho CY, Kwong RY, Desai MY, Dolman SF, Appelbaum E, Desvigne-Nickens P, DiMarco JP, Friedrich MG, Geller N, Harper AR, Jarolim P, Jerosch-Herold M, Kim DY, Maron MS, Schulz-Menger J, Piechnik SK, Thomson K, Zhang C, Watkins H, Weintraub WS, Kramer CM; HCMR Investigators.

J Am Coll Cardiol. 2019 Nov 12;74(19):2333-2345. doi: 10.1016/j.jacc.2019.08.1057.

PMID:
31699273
3.

Sex-related differences in exercise performance and outcome of patients with hypertrophic cardiomyopathy.

Ghiselli L, Marchi A, Fumagalli C, Maurizi N, Oddo A, Pieri F, Girolami F, Rowin E, Mazzarotto F, Cicoira M, Ribichini F, Arretini A, Targetti M, Passantino S, Cecchi F, Marchionni N, Maron M, Mori F, Olivotto I.

Eur J Prev Cardiol. 2019 Nov 7:2047487319886961. doi: 10.1177/2047487319886961. [Epub ahead of print]

PMID:
31698967
4.

Coexistence of acute takotsubo syndrome and acute coronary syndrome.

Sharkey SW, Kalra A, Henry TD, Smith TD, Pink VR, Lesser JR, Garberich RF, Maron MS, Maron BJ.

Catheter Cardiovasc Interv. 2019 Nov 6. doi: 10.1002/ccd.28595. [Epub ahead of print]

PMID:
31696663
5.

Net positive outcomes for nature.

Bull JW, Milner-Gulland EJ, Addison PFE, Arlidge WNS, Baker J, Brooks TM, Burgass MJ, Hinsley A, Maron M, Robinson JG, Sekhran N, Sinclair SP, Stuart SN, Zu Ermgassen SOSE, Watson JEM.

Nat Ecol Evol. 2019 Nov 4. doi: 10.1038/s41559-019-1022-z. [Epub ahead of print] No abstract available.

PMID:
31686021
6.

Impact of Sex on Clinical Course and Survival in the Contemporary Treatment Era for Hypertrophic Cardiomyopathy.

Rowin EJ, Maron MS, Wells S, Patel PP, Koethe BC, Maron BJ.

J Am Heart Assoc. 2019 Nov 5;8(21):e012041. doi: 10.1161/JAHA.119.012041. Epub 2019 Oct 30.

7.

The Guidant Affair revisited…but this time with good news.

Maron BJ, Harris KM, Maron MS.

Heart Rhythm. 2019 Oct 5. pii: S1547-5271(19)30916-6. doi: 10.1016/j.hrthm.2019.10.010. [Epub ahead of print] No abstract available.

PMID:
31593780
8.

Increasing evidence that risk scores underperform in predicting sudden death in hypertrophic cardiomyopathy.

Maron M, Rowin E, Maron BJ.

Heart. 2019 Sep 24. pii: heartjnl-2019-315694. doi: 10.1136/heartjnl-2019-315694. [Epub ahead of print] No abstract available.

PMID:
31551293
9.

Paradigm of Sudden Death Prevention in Hypertrophic Cardiomyopathy.

Maron BJ, Rowin EJ, Maron MS.

Circ Res. 2019 Aug 2;125(4):370-378. doi: 10.1161/CIRCRESAHA.119.315159. Epub 2019 Aug 1.

PMID:
31518168
10.

Offsetting impacts of development on biodiversity and ecosystem services.

Sonter LJ, Gordon A, Archibald C, Simmonds JS, Ward M, Metzger JP, Rhodes JR, Maron M.

Ambio. 2019 Sep 10. doi: 10.1007/s13280-019-01245-3. [Epub ahead of print]

PMID:
31506844
11.

Guideline-Based Referral for Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Is Associated With Excellent Clinical Outcomes.

Kimmelstiel C, Zisa DC, Kuttab JS, Wells S, Udelson JE, Wessler BS, Rastegar H, Kapur NK, Weintraub AR, Maron BJ, Maron MS, Rowin EJ.

Circ Cardiovasc Interv. 2019 Jul;12(7):e007673. doi: 10.1161/CIRCINTERVENTIONS.118.007673. Epub 2019 Jul 12.

PMID:
31296080
12.

Enhancing Medical Student-Interpreter Collaboration in an Urban Free Clinic.

Mazori AY, Maron MI, Osterbur ML Badhey, Santos D, Marco VF, Lin J, Cortijo A, Nosal S, Schoenbaum E.

Fam Med. 2019 Jul;51(7):593-597. doi: 10.22454/FamMed.2019.229662.

13.
14.

Structurally Normal Hearts Are Uncommonly Associated With Sudden Deaths in Athletes and Young People.

Thiene G, Rizzo S, Schiavon M, Maron MS, Zorzi A, Corrado D, Maron BJ, Basso C.

J Am Coll Cardiol. 2019 Jun 18;73(23):3031-3032. doi: 10.1016/j.jacc.2019.03.497. No abstract available.

PMID:
31196462
15.

Chronic Heart Failure Is Infrequently Associated With Renal Dysfunction in Hypertrophic Cardiomyopathy.

Rowin EJ, Romashko M, Testani JM, Koethe BC, Saxena D, Udelson JE, Maron BJ, Maron MS.

J Card Fail. 2019 Aug;25(8):690-692. doi: 10.1016/j.cardfail.2019.05.012. Epub 2019 May 31. No abstract available.

PMID:
31158468
16.

Assessing blue wildebeests' vigilance, grouping and foraging responses to perceived predation risk using playback experiments.

Dannock RJ, Pays O, Renaud PC, Maron M, Goldizen AW.

Behav Processes. 2019 Jul;164:252-259. doi: 10.1016/j.beproc.2019.05.021. Epub 2019 May 20.

PMID:
31121214
17.

Establishment of Specialized Clinical Cardiovascular Genetics Programs: Recognizing the Need and Meeting Standards: A Scientific Statement From the American Heart Association.

Ahmad F, McNally EM, Ackerman MJ, Baty LC, Day SM, Kullo IJ, Madueme PC, Maron MS, Martinez MW, Salberg L, Taylor MR, Wilcox JE.

Circ Genom Precis Med. 2019 Jun;12(6):e000054. doi: 10.1161/HCG.0000000000000054. Epub 2019 May 23.

PMID:
31117808
18.

Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy.

Maron MS, Rowin EJ, Wessler BS, Mooney PJ, Fatima A, Patel P, Koethe BC, Romashko M, Link MS, Maron BJ.

JAMA Cardiol. 2019 Jul 1;4(7):644-657. doi: 10.1001/jamacardio.2019.1391.

PMID:
31116360
19.

Influenza Antigen Engineering Focuses Immune Responses to a Subdominant but Broadly Protective Viral Epitope.

Bajic G, Maron MJ, Adachi Y, Onodera T, McCarthy KR, McGee CE, Sempowski GD, Takahashi Y, Kelsoe G, Kuraoka M, Schmidt AG.

Cell Host Microbe. 2019 Jun 12;25(6):827-835.e6. doi: 10.1016/j.chom.2019.04.003. Epub 2019 May 16.

PMID:
31104946
20.

Impact of Effective Management Strategies on Patients With the Most Extreme Phenotypic Expression of Hypertrophic Cardiomyopathy.

Rowin EJ, Maron BJ, Romashko M, Wang W, Rastegar H, Link MS, Maron MS.

Am J Cardiol. 2019 Jul 1;124(1):113-121. doi: 10.1016/j.amjcard.2019.04.002. Epub 2019 Apr 9.

PMID:
31027655
21.

Moving Beyond the Sarcomere to Explain Heterogeneity in Hypertrophic Cardiomyopathy: JACC Review Topic of the Week.

Maron BJ, Maron MS, Maron BA, Loscalzo J.

J Am Coll Cardiol. 2019 Apr 23;73(15):1978-1986. doi: 10.1016/j.jacc.2019.01.061. Review.

PMID:
31000001
22.

A composite measure of habitat loss for entire assemblages of species.

Simmonds JS, Watson JEM, Salazar A, Maron M.

Conserv Biol. 2019 Apr 13. doi: 10.1111/cobi.13331. [Epub ahead of print]

PMID:
30980558
23.

Program Development of Integrated Psychological Services for Hospitalized Patients with Intravenous Drug Use Histories.

Gill AD, McCuin T, Maron M.

J Clin Psychol Med Settings. 2019 Apr 4. doi: 10.1007/s10880-019-09616-4. [Epub ahead of print]

PMID:
30949791
24.

Safety, Side Effects and Relative Efficacy of Medications for Rhythm Control of Atrial Fibrillation in Hypertrophic Cardiomyopathy.

Miller CAS, Maron MS, Estes NAM III,, Price LL, Rowin EJ, Maron BJ, Link MS.

Am J Cardiol. 2019 Jun 1;123(11):1859-1862. doi: 10.1016/j.amjcard.2019.02.051. Epub 2019 Mar 13.

PMID:
30922542
25.

Letter by Maron et al Regarding Article, "Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)".

Maron BJ, Rowin EJ, Maron MS.

Circulation. 2019 Mar 19;139(12):1557-1558. doi: 10.1161/CIRCULATIONAHA.118.038189. No abstract available.

PMID:
30883223
26.

Clinical Course and Significance of Hypertrophic Cardiomyopathy Without Left Ventricular Hypertrophy.

Maurizi N, Michels M, Rowin EJ, Semsarian C, Girolami F, Tomberli B, Cecchi F, Maron MS, Olivotto I, Maron BJ.

Circulation. 2019 Feb 5;139(6):830-833. doi: 10.1161/CIRCULATIONAHA.118.037264. No abstract available.

PMID:
30715937
27.

Benefit of Cardiac Resynchronization Therapy in End-Stage Nonobstructive Hypertrophic Cardiomyopathy.

Rowin EJ, Mohanty S, Madias C, Maron BJ, Maron MS.

JACC Clin Electrophysiol. 2019 Jan;5(1):131-133. doi: 10.1016/j.jacep.2018.08.018. No abstract available.

PMID:
30678779
28.

Myocardial Strain in Hypertrophic Cardiomyopathy: A Force Worth Pursuing?

Maron MS, Wells S.

JACC Cardiovasc Imaging. 2019 Oct;12(10):1943-1945. doi: 10.1016/j.jcmg.2018.09.026. Epub 2019 Jan 16. No abstract available.

PMID:
30660525
29.

Case for Earlier Surgical Myectomy in Patients With Obstructive Hypertrophic Cardiomyopathy.

Maron MS, Spirito P, Maron BJ.

Circulation. 2018 Nov 6;138(19):2076-2078. doi: 10.1161/CIRCULATIONAHA.118.035484. No abstract available.

PMID:
30474424
30.

Metrics of progress in the understanding and management of threats to Australian birds.

Garnett ST, Butchart SHM, Baker GB, Bayraktarov E, Buchanan KL, Burbidge AA, Chauvenet ALM, Christidis L, Ehmke G, Grace M, Hoccom DG, Legge SM, Leiper I, Lindenmayer DB, Loyn RH, Maron M, McDonald P, Menkhorst P, Possingham HP, Radford J, Reside AE, Watson DM, Watson JEM, Wintle B, Woinarski JCZ, Geyle HM.

Conserv Biol. 2019 Apr;33(2):456-468. doi: 10.1111/cobi.13220. Epub 2018 Nov 22.

PMID:
30465331
31.

Summary of Presentations and Discussions of Hypertrophic Cardiomyopathy at the 2018 Boston International Summit VI Including Consensus, Controversies, and Unmet Needs.

Maron BJ, Maron MS.

Am J Cardiol. 2018 Oct 1;122(7):1281-1286. doi: 10.1016/j.amjcard.2018.06.018. Epub 2018 Jul 4. No abstract available.

PMID:
30173818
32.

Reply: Atrial Fibrillation in Hypertrophic Cardiomyopathy.

Maron MS, Udelson JE, Rowin EJ, Maron BJ.

JACC Heart Fail. 2018 Sep;6(9):807-808. doi: 10.1016/j.jchf.2018.06.009. No abstract available.

33.

Automated Cardiac MR Scar Quantification in Hypertrophic Cardiomyopathy Using Deep Convolutional Neural Networks.

Fahmy AS, Rausch J, Neisius U, Chan RH, Maron MS, Appelbaum E, Menze B, Nezafat R.

JACC Cardiovasc Imaging. 2018 Dec;11(12):1917-1918. doi: 10.1016/j.jcmg.2018.04.030. Epub 2018 Aug 15. No abstract available.

PMID:
30121270
34.

Clinical Spectrum and Management Implications of Left Ventricular Outflow Obstruction With Mild Ventricular Septal Thickness in Hypertrophic Cardiomyopathy.

Rowin EJ, Maron BJ, Chokshi A, Kannappan M, Arkun K, Wang W, Rastegar H, Maron MS.

Am J Cardiol. 2018 Oct 15;122(8):1409-1420. doi: 10.1016/j.amjcard.2018.06.055. Epub 2018 Jul 17.

PMID:
30107902
35.

Bold nature retention targets are essential for the global environment agenda.

Maron M, Simmonds JS, Watson JEM.

Nat Ecol Evol. 2018 Aug;2(8):1194-1195. doi: 10.1038/s41559-018-0595-2. No abstract available.

PMID:
29915340
36.

Left ventricular apical aneurysm in hypertrophic cardiomyopathy as a risk factor for sudden death at any age.

Rowin EJ, Maron BJ, Chokshi A, Maron MS.

Pacing Clin Electrophysiol. 2018 Jun 12. doi: 10.1111/pace.13413. [Epub ahead of print] Review.

PMID:
29893504
37.

Short-term response of a declining woodland bird assemblage to the removal of a despotic competitor.

Davitt G, Maute K, Major RE, McDonald PG, Maron M.

Ecol Evol. 2018 Apr 16;8(10):4771-4780. doi: 10.1002/ece3.4016. eCollection 2018 May.

38.

Response by Rowin et al to Letter Regarding Article, "Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy".

Rowin EJ, Maron MS, Maron BJ.

Circulation. 2018 Jun 5;137(23):2541-2542. doi: 10.1161/CIRCULATIONAHA.118.034857. No abstract available.

PMID:
29866781
39.

J Point Elevation in Hypertrophic Cardiomyopathy: Riding a New Wave in Risk Stratification?

Maron MS.

JACC Clin Electrophysiol. 2017 Oct;3(10):1143-1145. doi: 10.1016/j.jacep.2017.06.004. Epub 2017 Sep 13. No abstract available.

40.

Global Burden of Hypertrophic Cardiomyopathy.

Maron BJ, Rowin EJ, Maron MS.

JACC Heart Fail. 2018 May;6(5):376-378. doi: 10.1016/j.jchf.2018.03.004. Review. No abstract available.

41.

Association Between Race and Clinical Profile of Patients Referred for Hypertrophic Cardiomyopathy.

Wells S, Rowin EJ, Bhatt V, Maron MS, Maron BJ.

Circulation. 2018 May 1;137(18):1973-1975. doi: 10.1161/CIRCULATIONAHA.117.032838. No abstract available.

PMID:
29712699
42.

Response-Ivory crisis.

Biggs D, Smith RJ, Adams VM, Brink H, Cook CN, Cooney R, Holden MH, Maron M, Phelps J, Possingham HP, Redford KH, Scholes RJ, Sutherland WJ, Underwood FM, Milner-Gulland EJ.

Science. 2018 Apr 20;360(6386):277-278. doi: 10.1126/science.aat1596. Epub 2018 Apr 19. No abstract available.

PMID:
29674585
43.

Clinical Spectrum and Management of Heart Failure in Hypertrophic Cardiomyopathy.

Maron BJ, Rowin EJ, Udelson JE, Maron MS.

JACC Heart Fail. 2018 May;6(5):353-363. doi: 10.1016/j.jchf.2017.09.011. Epub 2018 Apr 11. Review.

44.

Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators.

Maron BJ, Casey SA, Olivotto I, Sherrid MV, Semsarian C, Autore C, Ahmed A, Boriani G, Francia P, Winters SL, Giudici M, Koulova A, Garberich R, Rowin EJ, Sears SF, Maron MS, Spirito P.

Circ Arrhythm Electrophysiol. 2018 Apr;11(4):e005820. doi: 10.1161/CIRCEP.117.005820.

PMID:
29625970
45.

Effect of Spironolactone on Myocardial Fibrosis and Other Clinical Variables in Patients with Hypertrophic Cardiomyopathy.

Maron MS, Chan RH, Kapur NK, Jaffe IZ, McGraw AP, Kerur R, Maron BJ, Udelson JE.

Am J Med. 2018 Jul;131(7):837-841. doi: 10.1016/j.amjmed.2018.02.025. Epub 2018 Mar 28.

PMID:
29604289
46.

Surgical Approaches to Hypertrophic Obstructive Cardiomyopathy.

Solomon Z, Breton C, Rowin EJ, Maron BJ, Maron MS, Chen FY, Rastegar H.

Semin Thorac Cardiovasc Surg. 2018 Summer;30(2):125-128. doi: 10.1053/j.semtcvs.2018.02.034. Epub 2018 Mar 7. Review.

PMID:
29524602
47.

Impact of Advanced Therapies for Improving Survival to Heart Transplant in Patients with Hypertrophic Cardiomyopathy.

Rowin EJ, Maron BJ, Abt P, Kiernan MS, Vest A, Costantino F, Maron MS, DeNofrio D.

Am J Cardiol. 2018 Apr 15;121(8):986-996. doi: 10.1016/j.amjcard.2017.12.044. Epub 2018 Jan 31.

PMID:
29496192
48.

Reach and messages of the world's largest ivory burn.

Braczkowski A, Holden MH, O'Bryan C, Choi CY, Gan X, Beesley N, Gao Y, Allan J, Tyrrell P, Stiles D, Brehony P, Meney R, Brink H, Takashina N, Lin MC, Lin HY, Rust N, Salmo SG 3rd, Watson JEM, Kahumbu P, Maron M, Possingham HP, Biggs D.

Conserv Biol. 2018 Aug;32(4):765-773. doi: 10.1111/cobi.13097. Epub 2018 Jun 20.

PMID:
29493821
49.

Cost shifting and other perverse incentives in biodiversity offsetting in India.

Narain D, Maron M.

Conserv Biol. 2018 Aug;32(4):782-788. doi: 10.1111/cobi.13100. Epub 2018 Mar 30.

PMID:
29473220
50.

Is It Fair to Screen Only Competitive Athletes for Sudden Death Risk, or Is It Time to Level the Playing Field?

Maron BJ, Estes NAM 3rd, Maron MS.

Am J Cardiol. 2018 Apr 15;121(8):1008-1010. doi: 10.1016/j.amjcard.2017.12.043. Epub 2018 Jan 31. No abstract available.

PMID:
29472006

Supplemental Content

Support Center